Please login to the form below

human growth hormone

This page shows the latest human growth hormone news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends Teva's generic version of Astellas' Advagraf

The committee also recommended that Faslodex could be used in combination with Pfizer ’s breast cancer drug Ibrance (palbociclib) to treat hormone receptor positive, human epidermal growth factor receptor 2-negative ... The combination can also be used

Latest news

Lilly gets early US approval for Ibrance rival abemaciclib

The US FDA has approved the CDK 4/6 inhibitor - which will be sold as Verzenio - as a combination treatment with hormone drug fulvestrant for hormone receptor-positive, human epidermal growth
Versartis crashes as VELOCITY trial veers off track

US biotech Versartis saw more than 80% wiped off its share price ahead of the weekend after its growth hormone deficiency drug somavaratan failed a phase III trial. ... The long-acting human growth hormone (hGH) product had been billed as a successor to
Surging Trulicity takes sting out of Lilly's arthritis setback

New chief executive David Ricks needs the drug and other growth brands to fire on all cylinders to help Lilly ride through the recent disappointment of a surprise FDA rejection for ... receptor-positive (HR+), human epidermal growth factor receptor
Pfizer keeps nose ahead of rivals with new Ibrance approval

The US FDA has converted its earlier conditional approval of Ibrance (palbociclib) into full approval as a first-line treatment of post-menopausal women with hormone receptor positive, human epidermal growth
FDA approval for Kisqali sets up showdown with Ibrance

menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.

More from news
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest Intelligence

Implementing eHealth innovation

Medications management and eHealth. The reference treatment for patients with GHD is based on recombinant human growth hormone (rhGH) which is identical to the growth hormone produced by the pituitary gland. ... growth hormone deficiency, one in which
Pharma deals during December 2014

costs. Pfizer has also signed up to a drug delivery product this month through its $570m licensing deal with Opko Health for a long acting version of human growth hormone (hGH), ... which is currently in phase III trials for the treatment of growth

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Pharma and free medicines: a different perspective

Palbociclib is approved for the treatment of patients with locally advanced or metastatic breast cancer, specifically those who have hormone receptor-positive and human epidermal growth factor receptor 2-negative disease. ... The committee found that

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Client Services Director - Med Comms: Great salary and bebefits

Home based, Editorial Team Leader, Medical Communications: Excellent package

Delivery Manager/ Head of Delivery – Executive Search: Neg

Senior Account Manager: Competitive salary commensurate with experience

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Client Services Director – Healthcare Advertising - London: Neg

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Manager: £40, 000 - £45, 000 benefits

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Home based, Chief Medical Writer, Medical Communications: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Business Unit Head, Medical Communications, London: Excellent package

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Home based, Principal Medical Writer, Medical Communications: Excellent package

Editorial Director – Medical Education (MedComms): Neg

Home based, Senior Medical Writer, Medical Communications: Excellent package

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Subscribe to our email news alerts

PMHub

Add my company

Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....